<p>We integrated histology, transcriptome, exome, and treatment outcomes of small cell neuroendocrine cancer (SCNC) from a range of metastatic sites, revealing complex intra- and intertumoral heterogeneity of neuroendocrine (NE) differentiation and transcriptomic subtypes (ASCL1, NEUROD1, POU2F3, YAP1 and ATOH1). High NE SCNCs were more likely to benefit from replication stress-targeted therapies, in contrast to non-NE tumors which were more likely to respond to immune response-targeted therapies.</p>

Integrated Genomic and Transcriptomic Analysis of Small Cell Lung Cancer    Reveals Inter- and Intratumoral Heterogeneity and a Novel    Chemotherapy-Refractory Subtype

Integrated Genomic and Transcriptomic Analysis of Small Cell Lung Cancer Reveals Inter- and Intratumoral Heterogeneity and a Novel Chemotherapy-Refractory Subtype

Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study.

Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress.